✦ LIBER ✦

Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study

✍ Scribed by G. P. Stathopoulos; D. Tsavdaridis; N. A. Malamos; S. K. Rigatos; Ch. Kosmas; N. Pergantas; J. G. Stathopoulos; J. Xynotroulas

Publisher: Springer
Year: 2005
Tongue: English
Weight: 194 KB
Volume: 56
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-005-1006-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of irinotecan and docet

A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer

✍ Sun Jin Sym; Heung Moon Chang; Hye Jin Kang; Sung Sook Lee; Min-Hee Ryu; Jae-Lyu 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 336 KB

A phase II study of weekly docetaxel in

A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer

✍ Hugo E. R. Ford; Yoon-Sim Yap; David W. Miles; Andreas Makris; Marcia Hall; Liz 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 311 KB

Phase II study of ifosfamide plus vinore

Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy

✍ F. Lobo; A. Frau; A. Barnadas; M. Méndez; J. Lizón; M. Provencio; J. J. Albistur 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 73 KB

Phase II study of ionidamine in patients

Phase II study of ionidamine in patients with metastatic breast cancer

✍ H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tor 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 193 KB

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi

A phase II trial of docetaxel (Taxotere®

A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer

✍ Martina Baur; Allan T. van Oosterom; Véronique Diéras; Michele Tubiana-Hulin; R. 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 385 KB

A phase II study of irinotecan in combin

A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer

✍ Takeshi Kato; Hideyuki Mishima; Masakazu Ikenaga; Kouhei Murata; Hideyuki Ishida 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 259 KB